313491-20-2

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 4-(1-(benzyloxycarbonyl)-2-methoxy-2-oxoethylidene)piperidine-1-carboxylate is used as a precursor in organic synthesis for the creation of various pharmaceutical compounds. Its complex structure and functional groups make it a valuable building block in the development of new organic molecules.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, tert-butyl 4-(1-(benzyloxycarbonyl)-2-methoxy-2-oxoethylidene)piperidine-1-carboxylate is utilized as an intermediate in the synthesis of potential drug candidates. Its presence of the benzyloxycarbonyl group is particularly advantageous for protecting amine groups during the synthesis process, which can be crucial for the stability and reactivity of the final product.
Used in Protecting Groups in Chemistry:
The benzyloxycarbonyl group in tert-butyl 4-(1-(benzyloxycarbonyl)-2-methoxy-2-oxoethylidene)piperidine-1-carboxylate is used as a protecting group for amine functions in chemical reactions. This feature is essential in organic synthesis to prevent unwanted side reactions and ensure the selective formation of desired products.
Used in Pharmaceutical Industry:
Tert-butyl 4-(1-(benzyloxycarbonyl)-2-methoxy-2-oxoethylidene)piperidine-1-carboxylate is used as a key intermediate in the pharmaceutical industry for the development of new drugs. Its unique structure and functional groups contribute to the design and synthesis of innovative therapeutic agents.
Overall, tert-butyl 4-(1-(benzyloxycarbonyl)-2-methoxy-2-oxoethylidene)piperidine-1-carboxylate is a multifaceted compound with applications spanning across various sectors of chemistry, particularly in the synthesis and development of pharmaceuticals. Its versatility and potential make it an important player in advancing chemical and medicinal research.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 

Downstream Products

• 368866-12-0 4-(amino-methoxycarbonyl-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 400888-21-3 4-((R)-benzyloxycarbonylamino-methoxycarbonyl-methyl)piperidine-1-carboxylic acid tert-butyl ester 
• 400888-22-4 4-((R)-benzyloxycarbonylamino-carboxy-methyl)piperidine-1-carboxylic acid tert-butyl ester 
• 177702-21-5 4-((R)-amino-carboxy-methyl)piperidine-1-carboxylic acid tert-butyl ester 
• 357413-57-1 (4'-methoxy-biphenyl-4-sulfonylamino)-[1-(2-methoxy-ethoxycarbonyl)-piperidin-4-yl]-acetic acid methyl ester 

Relevant academic research and scientific papers

Preparation method of 2-amino-2-(1-methyl-4-piperidyl)ethanol

The invention discloses a preparation method of 2-amino-2-(1-methyl-4-piperidyl) ethanol. The preparation method comprises the following steps: reacting 2-methyl-2-propyl-4-(1-amino-2-methoxy-2-oxoethyl)-1-piperidinecarboxylate (a compound II) with benzyl bromide under the action of an alkali 1 to generate a compound III; dissolving the compound III in an organic solvent, and generating a compound IV under the action of a reducing agent; and removing benzyl from the compound IV under the action of a catalyst/hydrogen to generate a compound I.

Compound, pharmaceutically acceptable salt thereof and medical application thereof

The invention belongs to the field of medicines, and particularly relates to a compound shown as a formula I or medicinal salt thereof. The invention also relates to application of the compound or themedicinal salt thereof in selectively inhibiting LF activity, resisting anthrax toxin toxicity and preventing or treating anthracnose.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.

ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C

The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56

ANTIVIRAL COMPOUNDS COMPOSED OF THREE ALIGNED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C

The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or preventing HCV infection in a patient.